

August 30, 2022



# PAVmed to Participate in the Lake Street 6th Annual Best Ideas Growth Conference and the A.G.P. Virtual MedTech Conference

NEW YORK--(BUSINESS WIRE)-- [PAVmed Inc.](#) (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a diversified commercial-stage medical device company operating in the medical device, diagnostics, and digital health sectors, today announced that Lishan Aklog, M.D., the Company’s Chairman and CEO, will participate in one-on-one investor meetings at Lake Street Capital Markets’ [6th Annual Best Ideas Growth \(BIG6\) Conference](#) to be held at [The Yale Club](#) in New York City on September 14, 2022, and during the [A.G.P. Virtual MedTech Conference](#) on September 21, 2022.

## About PAVmed

PAVmed Inc. is a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors. Its major subsidiary, Lucid Diagnostics Inc. (Nasdaq: LUCD) is a commercial-stage cancer prevention medical diagnostics company which markets the EsoGuard<sup>®</sup> Esophageal DNA Test and EsoCheck<sup>®</sup> Esophageal Cell Collection Device—the first and only commercial tools for widespread early detection of esophageal precancer to prevent esophageal cancer deaths. Lucid operates its own CLIA-certified, CAP-approved molecular diagnostic laboratory, LucidDx Labs and a network of Lucid Test Centers. Another major subsidiary, Veris Health Inc., is a digital health company focused on enhanced personalized cancer care through remote patient monitoring using implantable biologic sensors with wireless communication along with a custom suite of connected external devices. The product pipeline also includes the CarpX<sup>®</sup> Minimally Invasive Device for Carpal Tunnel Syndrome, EsoCure<sup>™</sup> Esophageal Ablation Device with CalduS<sup>™</sup> Technology, which complements EsoGuard and EsoCheck, NextFlo<sup>™</sup> Intravenous Infusion Set, PortIO<sup>™</sup> Implantable Intraosseous Vascular Access Device, and other earlier stage technologies. For more information on PAVmed, please visit [PAVmed.com](#) and follow PAVmed on [Twitter](#), [LinkedIn](#), and [YouTube](#). For more information on Lucid, please visit [LucidDx.com](#) and follow Lucid on [Twitter](#), and [LinkedIn](#). For detailed information on EsoGuard, please visit [EsoGuard.com](#) and follow EsoGuard on [Twitter](#), [Facebook](#) and [Instagram](#).

## Forward-Looking Statements

This press release includes forward-looking statements that involve risk and uncertainties. Forward-looking statements are any statements that are not historical facts. Such forward-looking statements, which are based upon the current beliefs and expectations of PAVmed’s management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Risks and uncertainties that may cause such

differences include, among other things, volatility in the price of PAVmed's common stock; general economic and market conditions; the uncertainties inherent in research and development, including the cost and time required to advance PAVmed's products to regulatory submission; whether regulatory authorities will be satisfied with the design of and results from PAVmed's clinical and preclinical studies; whether and when PAVmed's products are cleared by regulatory authorities; market acceptance of PAVmed's products once cleared and commercialized; PAVmed's ability to raise additional funding as needed; and other competitive developments. In addition, Lucid has been monitoring the COVID-19 pandemic and the pandemic's impact on PAVmed's businesses. Lucid expects the significance of the COVID-19 pandemic, including the extent of its effect on its financial and operational results, to be dictated by, among other things, the success of efforts to contain the pandemic and the impact of such efforts on PAVmed's businesses. These factors are difficult or impossible to predict accurately and many of them are beyond PAVmed's control. In addition, new risks and uncertainties may arise from time to time and are difficult to predict. For a further list and description of these and other important risks and uncertainties that may affect PAVmed's future operations, see Part I, Item IA, "Risk Factors," in PAVmed's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as the same may be updated in Part II, Item 1A, "Risk Factors" in any Quarterly Report on Form 10-Q filed by Lucid, as applicable, after its Registration Statement No. 333-259721 filed with the Securities and Exchange Commission. PAVmed disclaims any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in its expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.

View source version on businesswire.com:

<https://www.businesswire.com/news/home/20220830005230/en/>

Investors and Media:

Adrian K. Miller

PAVmed Inc.

[AKM@PAVmed.com](mailto:AKM@PAVmed.com)

Source: PAVmed Inc.